Business Context and Reporting Period
This Form 8-K Current Report was filed by Trxade Group, Inc. (Ticker: MEDS) on February 12, 2020, with the earliest event reported on February 13, 2020. The filing details a material definitive agreement for a public offering, a 1-for-6 reverse stock split, and the subsequent uplisting of the company's common stock on the NASDAQ Capital Market.
Key Financial Metrics and Capital Structure
- Offering Size: Sale of 806,452 shares of common stock (post-split) at $6.50 per share.
- Net Proceeds: Approximately $4.6 million after underwriting discounts and expenses.
- Use of Proceeds: Working capital, general corporate purposes, and potential acquisitions.
- Underwriting Fee: 8% of aggregate gross proceeds.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 120,967 additional shares.
- Capitalization: Approximately 6,539,410 shares outstanding post-split (excluding offering shares); 100,000,000 authorized shares.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics.
Material Changes Versus Prior Period
- Reverse Stock Split: Implemented a 1-for-6 reverse stock split effective February 13, 2020, reducing outstanding shares from approximately 39.2 million to 6.5 million.
- Listing Status: Transitioned to the NASDAQ Capital Market under the ticker symbol "MEDS" to meet the $4.00 minimum bid price requirement.
- Security Adjustments: Options, warrants, and convertible securities were adjusted by dividing share counts by 6 and multiplying exercise/conversion prices by 6.
Guidance, Outlook, and Risks
- Management Commentary: The reverse split was undertaken solely to satisfy NASDAQ listing requirements. Proceeds are intended to fund operations and strategic growth.
- Lock-Up Provisions: The Company, its officers, directors, and certain security holders agreed to a 180-day lock-up period prohibiting the sale of common stock or convertible securities without underwriter consent.
- Closing Date: The offering was expected to close on or about February 18, 2020.
- Risks: The filing notes customary representations and indemnification obligations but does not detail specific operational risks beyond the necessity of the reverse split for compliance.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received from the offering.
- Confirm the trading status and volume of the stock under the new ticker "MEDS" on the NASDAQ Capital Market.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific conditions to closing and indemnification terms.
- Check for any exercise of the 45-day over-allotment option by underwriters.
- Monitor subsequent filings for the actual deployment of the $4.6 million in proceeds.